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Leukotriene B4 (LTB4) is a potent chemoattractant associated with the development of 
osteoarthritis (OA), while its receptors BLT1 and BLT2 have been found in synovium and 
subchondral bone. In this study, we have investigated whether these receptors are also 
expressed by human cartilage cells and their potential effects on cartilage cells. 
The expression of LTB4 receptors in native tissue and cultured cells was assessed by 
immunohistochemistry, immunocytochemistry, PCR and electron microscopy. The functional 
significance of the LTB4 receptor expression was studied by Western blotting, using phospho-
specific antibodies in the presence or absence of receptor antagonists. In further studies, the 
secretion of pro-inflammatory cytokines, growth factors and metalloproteinases by LTB4 -
stimulated chondrocytes was measured by multiplex protein assays. The effects of LTB4 in 
cartilage signature gene expression in cultured cells were assessed by qPCR, whereas the 
LTB4-promoted matrix synthesis was determined using 3D pellet cultures. 
Both receptors were present in cultured chondrocytes, as was confirmed by immunolabelling 
and PCR. The relative quantification by PCR demonstrated a higher expression of the 
receptors in cells from healthy joints compared with OA cases. The stimulation of cultured 
chondrocytes with LTB4 resulted in a phosphorylation of downstream transcription factor Erk 
1/2, which was reduced after blocking BLT1 signalling. No alteration in the secretion of 
cytokine and metalloproteinases was recorded after challenging cultured cells with LTB4; 
likewise, cartilage matrix gene expression and 3D tissue synthesis were unaffected.  
Chondrocytes express BLT1 and BLT2 receptors, and LTB4 activates the downstream Erk 1/2 
pathway by engaging the high-affinity receptor BLT1. However, any putative role in cartilage 
biology could not be revealed, and remains to be clarified.  






The metabolism of arachidonic acid by the cyclooxygenase (COX) or 5-lipoxygenase (5-LO) 
pathways generates eicosanoids, which have been implicated in the pathophysiology of a 
variety of human diseases, including arthritis of the joints (Molloy and McCarthy, 2005; 
Korotkova and Jakobsson, 2014).  
Arachidonic acid released from cell membranes by events such as inflammation or trauma can 
be converted to unstable precursor leukotriene A4 (LTA4) via the 5-LO and 5-lipoxygenase 
activating protein (FLAP), and further into leukotriene B4 (LTB4) by LTA4 hydrolase (Peters-
Golden and Henderson, 2007). In the presence of COX-1 or COX-2, arachidonic acid is 
converted into prostaglandin H2, and subsequently into prostaglandin E2 by prostaglandin E 
synthase (Li et al., 2009). Leukotriene B4 (LTB4) is a powerful inflammatory mediator 
implicated in diseases such as asthma, atherosclerosis and rheumatoid arthritis by the 
recruitment and activation of leukocytes (Tager and Luster, 2003; Peters-Golden and 
Henderson, 2007; Di Gennaro and Haeggstrom, 2014). Importantly, LTB4 levels are enhanced 
in synovial tissue and -fluid, cartilage and subchondral bone during both osteoarthritis (OA) 
and rheumatoid arthritis (RA) (Ahmadzadeh et al., 1991; Wittenberg et al., 1993; Paredes et 
al., 2002; Attur et al., 2012). 
LTB4 binds two G-coupled receptors: the high-affinity leukotriene B4 receptor 1 (BLT1) and 
the low-affinity leukotriene B4 receptor 2 (BLT2) (Yokomizo et al., 2001a). The BLT1 
receptor was initially described in humans in myeloid cells (Yokomizo et al., 1997), though 
later studies have reported its presence in non-myeloid tissues as well, including subchondral 
osteoblasts and synovial cells (Paredes et al., 2002; Hashimoto et al., 2003). BLT1 activation 
in non-myeloid cells promotes the cell differentiation, migration, proliferation and chemokine 




expressed in humans (Yokomizo et al., 2000), while in synovial tissue the expression of 
BLT2 surpasses that of BLT1 (Hashimoto et al., 2003). 
Prostaglandins are also involved in OA development (Amin et al., 1997; Li et al., 2009), with 
the current first-line treatment of OA including COX inhibitors (McAlindon et al., 2014). 
However, blocking COX-regulated arachidonic acid pathways leads to a shunting of the 
system to the 5-LO pathway, as well as an undesired elevation of LTB4 levels (Marcouiller et 
al., 2005; Maxis et al., 2006; Attur et al., 2012).  
Despite studies arguing for the importance of LTB4 and its receptors on RA and OA disease 
development, the expression and function of LTB4 receptors in chondrocytes has not yet been 
reported. The aim of this study was to assess the expression of LTB4 receptors BLT1 and 
BLT2 in cartilage and the biological effects of LTB4 on cultured chondrocytes. 
Material and method 
Human material and cell culturing 
Macroscopically healthy looking cartilage was harvested from the lateral femoral condyle of 
15 patients (age 55-82) undergoing total knee replacement (TKR), and the overall grading of 
cartilage according to the ICRS/Outerbridge score (Kleemann et al., 2005) was 2-4. In 
addition, we obtained surplus cells from the autologous chondrocyte implantation (ACI) of 10 
patients (aged 31-65); these cells were harvested and expanded as previously described 
(Brittberg et al., 1994; Peterson et al., 2002), with the procedure also demanding a normal 
joint on X-ray and arthroscopy (Knutsen et al., 2004). The patients participated by informed 
consent, and the Regional Ethical Committee of North Norway approved the study. 
Cartilage from TKR was kept in a sterile saline and processed within two hours from harvest. 
Specimens were processed directly as described for immunohistochemistry and electron 
microscopy, enzymatically digested for the determination of BLT receptors and signature 




by digestion in 0.8 mg/mL of collagenase XI solution (Cat. no. C9407, Sigma-Aldrich) for 
four hours at 37°C during gentle agitation. Chondrocytes were plated in 25cm2 culture flasks 
containing Dulbecco’s Modified Eagle’s Medium/Ham’s F-12 Mixture (DMEM/F-12), and 
supplemented with ascorbic acid (62 mg/L), penicillin (2500 U/L), streptomycin (2.5 mg/L) 
and 20% fetal bovine serum (FBS, Cat. no. S0115, Biochrome). After cell attachment, 
cultures were further propagated in a medium supplemented with 10% serum and the cell 
number was serially expanded in appropriate vessels, and subsequently used for 
experimentation at passages 3-4.  
Immunohistochemistry and immunocytochemistry 
The immunolabelling of BLT1 and BLT2 receptors in native cartilage and cultured 
chondrocytes was performed using polyclonal rabbit anti-human BLT1 antibody (Cat. no. 
120114, Cayman Chemicals), and/or polyclonal rabbit anti-human BLT2 antibody (Cat. no. 
120124, Cayman Chemicals) or no primary antibody for control. For immunohistochemistry, 
biopsies from five TKR donors were fixed in paraformaldehyde and prepared as previously 
described (Berg et al., 2010). Sections were incubated overnight at 4°C in BLT1 or BLT2 
antibody diluted at 1:100. Slides were stained using an Anti-rabbit HRP SuperPicTure™ 
Polymer detection kit (Cat. no. 87-9263, Invitrogen), and counterstained with haematoxylin. 
Isotype control was used to assess non-specific binding. For immunocytochemistry, an 
appropriate number of expanded chondrocytes from four TKR donors were seeded on 
fibronectin-coated slides as previously described (Berg et al., 2010). Slides were incubated 
overnight at 4°C in BLT1 or BLT2 antibody diluted at 1:250. After washing in PBS, the slides 
were incubated with secondary antibody Alexa Fluor® Goat Anti-Rabbit IgG (Cat. no. 
A11008, Invitrogen) at 4°C for four hours until nuclear staining and mounting using DAPI-
Fluoromount-G™ (Cat. no. 0100-20, Southern Biotech). The slides were examined in a Zeiss 




RT-PCR of BLT1 and BLT2 mRNAs 
As previously described, a reverse-transcription PCR was performed (Berg et al., 2010). In 
brief, total RNA was extracted from two different TKR cell cultures using an RNeasy® Mini 
Kit (Cat. no. 74106, Qiagen), and converted to cDNA using a Superscript® III Reverse 
Transcriptase (Cat. no. 18080-093, Invitrogen). The PCR reaction volume of 50 µL included 
5 µL cDNA, 150 nM of each specific primer, ultrapure water and MasterMix (Cat. no 
PRME2200100, 5 Prime). Sequences for the specific primers for human BLT1 (sense 5'-
TATGTCTGCGGAGTCAGCATGTACGC-3', antisense 5'-
CCTGTAGCCGACGCCCTATGTCCG-3') yields a 345 bp product, while human BLT2 
(sense 5'-AGCCTGGAGACTCTGACCGCTTTCG-3', antisense 5'-
GACGTAGAGCACCGGGTTGACGCTA-3') yields a 320 bp product. Adenine 
phosphoribosyltransferase (APRT) (sense 5’-CCCGAGGCTTCCTCTTTG GC-3’, antisense 
5’-CTCCCTGCCCTTAAGCGAGG-3’) which yields a 300 bp product, was included for 
RNA quality control; in case of contaminating DNA, a 800 bp product would occur. The PCR 
was run on a GeneAmp® PCR System 9700 (Applied Biosystems), with an amplification 
profile of: 7 minutes at 94°C (denaturation), 30 seconds at 94°C (denaturation), 30 seconds at 
55°C (annealing), 1 minute at 72°C (extension) and 30 cycles completed with a 10-minute 
extension at 72°C. RT-PCR products were separated on Novex® 6% TBE gel (Cat. no. 
EC6265BOX, Invitrogen) and stained with SYBR® Safe DNA gel stain (Cat. no. S33102, 
Invitrogen), while images were developed using a G-Box (Syngene). To help confirm that 
BLT1 and BLT2 transcripts matched those reported in GeneBank®, the PCR products were 
sequenced using a BigDye® Terminator v3.1 Cycle Sequencing Kit (Cat.no 4337455, 




Immuno Electron microscopy 
Cartilage specimens from two different TKR donors were freshly collected, washed in ice-
cold PBS and fixed in 4% formaldehyde in a 200 mM HEPES buffer, pH 7.5, for 24 hours. 
Cryosections were prepared, and immunolabelling was performed as described elsewhere 
(Tokuyasu, 1986). Antibodies against BLT1 (diluted 1:20) were detected by protein A-gold 
complexes, and the dried sections were then examined in a JEOL JEM 1010 transmission 
electron microscope (JEOL, Tokyo, Japan) operating at 80 kV. Additionally, negative 
controls were routinely included in parallel by the omission of primary antibodies. 
Relative quantification of BLT1 and BLT2 receptor by qPCR 
RNA was extracted from three sources: cartilage biopsies from total knee replacement 
biopsies (N=3), cultured cells from total knee replacement biopsies at passage 4 (N=5) and 
surplus cells from ACI at passage 4 (N=5). For RNA extraction from cartilage, the biopsies 
were minced to ~1mm3 pieces, and chondrocytes were then rapidly released by digestion in a 
0.25% trypsin solution (Cat. no. T3924, Sigma-Aldrich) for 60 minutes and then in a 0.8 
mg/mL collagenase XI solution for six hours at 37°C during gentle agitation. The freshly 
isolated cells were lysed using Qiazol, followed by DNase I treatment and cleanup on RNeasy 
mini-spin columns (Cat. no. 74804, Qiagen) according to the manufacturer’s instructions. 
Cultured cells were then extracted using a PerfectPure RNA Cultured Cell Kit (Cat. no. 
2302340, 5 prime), including DNase I treatment according to the manufacturer’s instructions. 
RNA was quantified by spectrophotometry (Nano Drop ND-1000), and diluted at 1:5 to a 
final concentration of 9.82 ng/µL before reverse transcription (RT) using a High Capacity 
RNA to cDNA kit (Cat. no. 4387406, Invitrogen) according to the manufacturer’s 
instructions. The relative quantification experiment was run with hydrolysis probes targeting 
BLT1 (LTB4R, Hs01938704_s1) and BLT2 (LTB4R2, Hs01885851_s1). Based on previous 




Life Technologies) was used as the reference gene. The reaction volume of 10 µL included 5 
µL TaqMan® Fast Universal PCR Mastermix No AmpErase® UNG (Cat. no. 4366072, 
Applied Biosystems), 2.5 µL water, 2 µL cDNA (50 ng/µL) and 0.5 µL of the respective 
assays. Three technical replicates of each sample were applied to a MicroAmp® Fast Optical 
96-well reaction plate (Cat. no. 4346906, Applied Biosystems), and water and no-RT samples 
were added for the negative control. The plates were run on StepOnePlus, using the following 
cycling conditions: hold at 95°C for 20 seconds, 40 cycles at 95°C for one second and then at 
60°C for 20 seconds. Data was analysed in Microsoft Excel, a t-test was used to test 
significance and the differences were considered significant at p < 0.05.  
Western blotting of phosphorylated protein kinases 
Cultured chondrocytes from three ACI donors were starved for 24 hours before LTB4 (Cat. 
no. 20110, Cayman Chemicals) was added at a final concentration of 10-8 M for 3 and 5 
minutes each. For inhibition studies, cultured chondrocytes were challenged with BLT1 
receptor antagonist U-75302 at 3 x 10-7 M (Cat. no. 70705, Cayman Chemicals) or BLT2 
receptor antagonist LY2552833 at 10-6 M (Cat. no. 70715, Cayman Chemicals) for 1 hour 
before being stimulated with LTB4 for 5 minutes (Yokomizo et al., 2001b; Lundeen et al., 
2006). Cells were lysed in a 150 µL radioimmunoprecipitation (RIPA) buffer (Cat. no. 20-
188, Millipore), including protease- and phosphatase inhibitor, and an equal amount of 
protein was separated with gel electrophoresis and blotted to PVDF membranes. Membranes 
were incubated overnight at 4°C with Phospho-p44/42 MAPK (Erk 1/2) Rabbit mAb (Cat. no. 
4370, Cell Signaling) and loading control β-actin (13E5) Rabbit mAb (Cat. no. 4970, Cell 
Signaling) at a final dilution of 1:2000. Next, the membranes were incubated for 1 hour with 
Anti-rabbit IgG HRP-linked Antibody (Cat. no. 7074, Cell Signaling), and bands were 




Multiplex protein analyses 
The protein concentration in culture supernatants was analysed by antibody-based multiplex 
protein arrays. Chondrocytes from three different TKR cultures were seeded on 24-well plates 
at a concentration of 1.0x105 cells/well, and incubated overnight in a medium with a 10% 
FBS. Thereafter the cells were starved overnight in a medium containing 0.1% FBS before 
challenging with LTB4 at a concentration of 10
-12 M, 10-10 M, 10-8 M or vehicle only at 37°C 
for 18 hours. Vascular endothelial growth factor (VEGF), basic fibroblast growth factor 
(bFGF) and platelet-derived growth factor (PDGF), along with inflammatory cytokines IL-1β, 
TNF-α, IL-6, IL-8 and MCP-1, were analysed in an 8-plex assay (Cat. no. Z50007ZORG, Bio 
Rad). Matrix metalloproteinases (MMP) of -1, -2, -3, -8, -9 and -13 were measured using a 
multiplex MMP assay (Cat .no. LMP000, R&D Systems). Samples were diluted at 1:4 and 
analysed in duplicate using the Bio-Plex 200 System (Bio-Rad). The results are the average of 
two independent experiments, and were analysed in Excel using a one-way ANOVA. 
qPCR of cartilage signature genes 
Surplus cultured chondrocytes from four ACI procedures were grown in parallel, in which 
one culture remained untreated for the control, and the other stimulated with LTB4 at a final 
concentration of 10-8 M for 18 hours. Chondrocytes were harvested in a lysis solution and 
RNA extracted using the PerfectPure RNA Cultured Cell Kit (Cat. no. 2302340, 5 prime) 
according to the manufacturer’s instructions, including DNase I treatment. RNA was 
quantified using Nano Drop ND-1000, and converted to cDNA with a High Capacity RNA to 
cDNA kit (Cat. no. 4387406, Invitrogen) according to the manufacturer’s instructions. For the 
qPCR, the following pre-optimized hydrolysis probes from Applied Biosystems were used: 
Collagen 1A1 (COL1A1, Assay ID: Hs00164004_m1), Collagen 2A1 (COL2A1, Assay ID: 
Hs00264051_m1), Aggrecan (ACAN, Assay ID: Hs00153936_m1) and SOX9 (SOX9, Assay 
ID: Hs00165814_m1). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH, Assay ID: 




monolayer cultures. A reaction volume of 20 µL contained 10 µL of TaqMan® Fast Universal 
PCR Mastermix No AmpErase® UNG (Cat. no. 4366072, Applied Biosystems), 7 µL of 
water, 2 µL of cDNA (50 ng/µL) and 1 µL of the respective assays. Samples in three 
technical replicates were applied to a MicroAmp® Fast Optical 96-well reaction plate (Cat. 
no. 4346906, Applied Biosystems); water for a negative control and cDNA from freshly 
isolated cartilage cells were added in triplicate for positive control and interplate calibration. 
Plates were analysed on an Applied Biosystems 7900HT Fast Real-Time PCR System with 
the following cycling conditions: hold at 95°C for 20 seconds, 40 cycles at 95°C for one 
second and then 60°C for 20 seconds. 
3D Pellet cultures 
Surplus ACI chondrocytes expanded in monolayers were detached by an enzyme-free 
detachment solution (Cat. no. S-004-B, Millipore) and a short (30 seconds) trypsinization. 
Cells were then resuspended in a complete growth medium, and 150 µL aliquots (50000 cells) 
were added to Nunc™ 96-well polystyrene conical bottom MicroWell™ plates (Cat. no. 
249935, Thermo Scientific) and centrifuged at 400 x g for 10 minutes to make pellets. After 
two days, rounded shaped and consistent spheroids were transferred to a low attachment 24-
well plate in a serum-free medium containing ITS (Insulin-Transferrin-Selenite, Cat. no. 
354352, BD Biosciences). For the treated group, 10-8 M LTB4 was added to the medium. 
Spheroids were further incubated for six days, and the medium with or without LTB4 was 
changed every second day. Lastly, spheroids were collected and prepared for histology as 
described under immunohistochemistry. To evaluate the matrix synthesis, slides were stained 
with Alcian blue to detect glycosaminoglycans or a collagen type II antibody. 
Results 
Initial experiments were performed to assess the expression of LTB4 receptors in cartilage 




using BLT1 or BLT2 antibodies. A positive brown staining confirmed the presence of BLT1 
receptor (Figure 1a) and BLT2 receptor (Figure 1b), while immunocytochemistry using 
respective antibodies showed that cultured chondrocytes at passages 3-4 also expressed BLT1 
(Figure 2a) and BLT2 receptors (Figure 2b). The expression of mRNA encoding these 
receptors was confirmed by RT-PCR using specific BLT1 and BLT2 primers, as shown in 
Figures 3a and 3b, respectively. The sequencing of the products revealed an identical 
sequence to the GeneBank sequence for BLT1 and BLT2 (data not shown). The subcellular 
distribution of the BLT1 receptor was assessed by immune electron microscopy, and the 
specific detection of BLT1 by immune-gold labelling exhibited a predominant expression of 
the receptor in the plasma membrane of chondrocytes from native tissue, and to a much lesser 
extent in cytoplasm (Figures 4 A-D). The relative qPCR revealed that the expression of BLT1 
was significantly higher in cultured chondrocytes from non-OA joints (ACI) than cartilage 
biopsies from OA cases (TKR) (Figure 5 A). Likewise, the gene expression of BLT1 was 
significantly higher in cartilage compared to cultured cells from TKR (Figure 5 C). The 
expression of BLT2 was higher in cultured ACI cells compared to cultured TKR cells, but 
equally expressed in expanded TKR cells and cartilage (Figure 5 B, D). 
In order to assess the BLT1 and BLT2 downstream signalling, cells were stimulated with 10-8 
M LTB4, followed by the Western blotting of Phospho-Erk 1/2 (p44/42 MAPK). Figure 6 
shows a modest background phosphorylation of Erk 1/2 in untreated chondrocytes (Lane 1); 
however, an LTB4 challenge for five minutes markedly increased phosphorylation (Lane 3). 
The blocking of the BLT1 receptor with the specific receptor antagonist U-75302 before the 
LTB4 challenge reduced the signal to background phosphorylation (Lane 4). In contrast, a 
specific blockage of the BLT2 receptor with the antagonist LY2552833 had no major impact 





Having confirmed the expression of functional BLT1 in chondrocytes, we assessed the 
potential effects of LTB4 on major biological parameters in subsequent experiments. A 
multiplex analysis of supernatants of chondrocytes cultured in the presence of LTB4 at 
increasing doses revealed no significant change in the secretion of growth factors, pro-
inflammatory cytokines or MMPs. Levels of bFGF, PDGF, IL-1β, TNF-α, MMPs 1, 2, 8 and 
9 were undetectable, with values falling under the detection limit of the assay in both the 
treated and untreated groups. VEGF, IL-6, IL-8, MCP-1 and MMPs 3 and 13 were detected, 
although LTB4 did not significantly alter the secretion of these molecules when analysed 
using ANOVA (Figure 7).  
To assess the potential effect of LTB4 on chondrocytes differentiation, the expression of some 
cartilage signature genes, including Aggrecan, Sox-9, Collagen 1A1 and Collagen 2A1, were 
analysed using qPCR. Four biological replicates were included, and data were normalized 
against GAPDH. Relative gene expression in chondrocytes stimulated with 10-8 M LTB4 
normalized to untreated controls is illustrated in Figure 8. Furthermore, stimulating cultured 
chondrocytes with LTB4 did not alter the expression of specific cartilage signature matrix 
genes. 
Lastly, the cartilage-forming capability of cultured chondrocytes was assessed in the presence 
or absence of 10-8 M LTB4. After six days, tissue with the characteristics of “immature” 
cartilage was formed in both settings, revealing similar features regarding size, shape, the 
amount of extracellular matrix and cell density. Specific staining with Alcian blue for the 
detection of glycosaminoglycans, and with anti-collagen type II antibodies to evaluate the 
LTB4 effect on matrix synthesis, demonstrated no observable differences (Figure 9). 
Discussion 
A potential role of LTB4 in RA and OA has been suggested based on cell culture and tissue 




demonstrating the presence of BLT1 and BLT2 receptors in synovial tissue and subchondral 
bone (Paredes et al., 2002; Hashimoto et al., 2003; Attur et al., 2012). Moreover, LTB4 
receptor knock-out mice were protected from rheumatoid arthritis development (Kim et al., 
2006; Mathis et al., 2010). In the present study, we show for the first time that the LTB4 
receptors BLT1 and BLT2 are expressed by human chondrocytes, both in vivo and in vitro. 
Additionally, subcellular localization studies of cartilage tissue using cryo-immuno electron 
microscopy unveiled a predominant expression of BLT1 at the plasma membrane in 
chondrocytes from native tissue.  
One of the important findings of our study was the differential expression of BLT1 and BLT2 
in chondrocytes from OA vs. healthy patients. A quantitative PCR analysis revealed that both 
BLT1 and BLT2 expression was higher in cartilage cells from non-diseased joints. This 
downregulation of receptor expression in diseased tissue could represent a protective 
mechanism to help ameliorate tissue damage caused by chronic inflammation. Likewise, the 
expression of the BLT1 receptor diminished during cell expansion in monolayers (Figure 5), 
with this outcome possibly being part of the overall cellular dedifferentiation process 
undergone by chondrocytes during expansion in monolayer cultures. 
Previous studies with non-myeloid cells have reported that LTB4 stimulation results in the 
downstream phosphorylation of signal transduction factors such as Akt and Erk 1/2, as well as 
the subsequent enhancement of migration and proliferation (Lundeen et al., 2006; Watanabe 
et al., 2009). In the present study, we could see evidence of an increased downstream 
phosphorylation of the BLT1 receptor when chondrocytes were stimulated with LTB4. The 
signal appears to be mediated via the BLT1 receptor, as blocking with the BLT1 receptor 
antagonist U-75302 led to less phosphorylation of Erk 1/2, while blocking BLT2 did not 




Earlier studies have shown that chondrocytes secrete a wide range of growth factors, 
cytokines and MMPs (Berg et al., 2010; Polacek et al., 2010; Polacek et al., 2011). A critical 
phenomenon associated with the onset and progression of OA is the enhanced expression of 
MMPs within the joint tissue (Goldring and Marcu, 2009), with pro-inflammatory cytokines 
such as IL-1β and TNF-α being strong inducers of MMP production and driving forces in 
cartilage deterioration (Martel-Pelletier, 2004). The endogenous synthesis of LTB4 by 
synovium is a crucial element involved in the upregulation of IL-1β and TNFα in OA (He et 
al., 2002). We therefore hypothesized that the secretion of MMPs, cytokines and/or growth 
factors would be affected by LTB4 stimulation. In our analyses, MMP-3, MMP-13, VEGF, 
IL-6, IL-8 and MCP-1 were readily detected in culture supernatants, though their synthesis 
was not altered by LTB4 at any dose tested (Figure 7). The secretion of other mediators, 
including TNF-α and IL-1β, was below the detectable range. In vivo, the production of MMPs 
is promoted by IL-1 and TNF-(Martel-Pelletier et al., 2004 Thus, a reasonable 
assumption is that the levels of these pro-inflammatory cytokines were insufficient in our 
assays, or that other synergistic factors required were not present in our in vitro systems.  
The most prominent physiological role of chondrocytes is the homeostasis of the extracellular 
matrix and the maintenance of cartilage integrity (Goldring and Marcu, 2009). In this regard, 
the gene expression of specific cartilage matrix molecules is used as a functional marker of 
chondrocyte phenotype and differentiation status. It has previously been reported that in 
cultured chondrocytes stimulated with PGE2, aggrecan gene expression was significantly 
downregulated, whereas the gene encoding collagen type II remained unchanged (Attur et al., 
2008). Our data revealed an unaltered gene expression of collagen type 1A1, collagen type 
2A1, aggrecan or Sox9 after 18 hours of incubation with LTB4 (Figure 8). The decreased 
expression of BLT1 receptors observed after monolayer expansion might be the cause of the 




When chondrocytes are cultured in monolayers, they gradually dedifferentiate into a more 
fibroblast-like cell, a transformation characterized by an upregulation of collagen I and a 
downregulation of collagen II. In pellet cultures, the cells partially regain their original 
phenotypic traits in a process involving the downregulation of mitotic activity and the 
upregulation of matrix synthesis (Martinez et al., 2008). Intriguingly, the treatment of 
chondrocytes in 3D pellets with the PGE2 has been shown to reduce collagen types I and II 
content (Jakob et al., 2004). We hypothesized that adding LTB4 during 3D cultures could 
affect chondrocyte redifferentiation and matrix synthesis, but in our hands there was no 
marked difference in the morphological or immunohistochemical characteristics of the 3D 
constructs (Figure 9). 
Concluding remarks 
We have demonstrated that human articular chondrocytes express LTB4 receptors BLT1 and 
BLT2, and that at least the BLT1 receptor is functional, as shown by its capability to activate 
intracellular signalling pathways upon ligand binding. The physiological role of these 
receptors in human chondrocytes, particularly during joint inflammation, requires further 
investigation.  
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Figure 1: Expression of BLT1 and BLT2 in cartilage tissue (60x micrograph). Cartilage 
tissue sections stained with BLT1 antibody (1a), BLT2 antibody (1b) and isotype control (1c).  
Figure 2: Expression of BLT1 and BLT2 in cultured chondrocytes. 
Immunofluorescence microscopy of cultured chondrocytes stained with BLT1 antibody (2a), 
BLT2 antibody (2b). Secondary antibody conjugated with Alexa Fluor488 and DAPI stained 
nuclei. Isotype controls had no staining (not shown). Scalebar = 50µm. 
Figure 3: Expression of BLT1 and BLT2 mRNA in cultured chondrocytes by Reverse 
Transcriptase PCR. 3a: Lane L: DNA ladder, Lanes 1 and 2: mRNA control, APRT primer 
yields 300 bp bands and no trace of the 800 bp bands that appears when APRT is primed to 
genomic DNA (Lane 7). Lanes 4 and 5: cDNA from two donors and specific BLT1 primers 
yield 345 bp bands. Lanes 3 and 6: Negative control. 3b: Lane L: DNA ladder. Lane 1: 
mRNA control. Lane 2: Negative control. Lanes 3 and 4: cDNA from two donors and specific 
BLT2 primers yield 320 bp bands.  
Figure 4: Subcellular localization of BLT1 receptors in cartilage cells by immune-cryo 
electron microscopy. 4a and 4c: Two different cartilage sections stained with gold-
conjugated anti-BLT1 antibody binding to BLT1 receptor in plasma membrane Panels 4b and 
4d are enlarged windows of 4a and 4c, respectively. Gold particles are marked with arrow 
heads. CP = cytoplasm, N = nucleus, PM = plasma membrane, ECM = extracellular matrix. 
Scale bars = 1µm 
Figure 5: Differential expression of BLT1 and BLT2 mRNA in cartilage cells from OA 
vs non-OA. Expression of BLT1 (5A) and BLT2 (5B) in cultured cells from five healthy ACI 




is a comparison of cartilage from TKR to cultured cells from TKR for BLT1 and BLT2, 
respectively. 
Figure 6: Functional assessment of BLT receptors by Western blot. p-Erk 1/2 (44/42 kD). 
Lane L: Biotinylated ladder. Lanes 1-3: Erk 1/2 phosphorylation at 0, 3 and 5 minutes 
exposure to LTB4. Lanes 4: Phosphorylation of Erk 1/2 in presence of BLT1 receptor 
antagonist (U-75302 at 3 x 10-7 M). Lane 5: Phosphorylation of Erk 1/2 in presence of BLT2 
receptor antagonist (LY2552833 at 10-6 M). Lane 6: Phosphorylation of Erk 1/2 in presence 
of both receptor antagonists. Beta-actin (45kD) was used as loading control. 
Figure 7: Secretion of growth factors, MMPs and inflammatory mediators after 
stimulation of chondrocytes by LTB4. Levels measured in supernatants from cultured 
chondrocytes after 24 hours of stimulation with LTB4 at concentrations of 10
-12M, 10-10M, 10-
8M and vehicle. 
Figure 8: Cartilage signature gene expression by qPCR. Relative expression of cartilage 
signature genes in cultured chondrocytes challenged with LTB4 for 18h. Results are 
normalized to untreated chondrocytes. A cartilage sample was included to visualize 
expression in cartilage vs. cultured cells. P-values are a result of t-testing cartilage vs. control 
and treated vs. control, respectively. 
Figure 9: Histology and immunohistochemistry of scaffold-free 3D chondrocyte 
spheroids. Chondrocyte pellets incubated for six days with LTB4 at 10
-7 M vs. unchallenged 
controls. Brown colour corresponds to expression of collagen type II, whereas the blue colour 
is indicative of matrix proteoglycans. The folds in the upper left- and lower right image are 
artefacts of preparation. Scalebar = 200 µm.  








